Sagimet Biosciences Inc. SGMT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
16.22
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$51.0M | — | — | $111.4M |
| 2024 | — | -$45.6M | — | — | $155.8M |
| 2023 | $2.0M | -$27.9M | — | — | $91.1M |
| 2022 | — | -$30.5M | — | — | -$186.9M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 16.22 (safe)
- Working capital / assets 0.956
- Retained earnings / assets -2.973
- EBIT / assets -0.488
- Equity / liabilities 21.835
Source: SEC EDGAR filings · CIK 0001400118 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.